Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

Inclusion Criteria:

- Age 12 to 17.

- Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD.

- History of AD for ≥1 year.

- History of topical corticosteroid (TCS; Europe: Class 3 or higher; US: Class 4 or
lower) and/or topical calcineurin inhibitor (TCI) treatment failure or subjects for
whom these topical AD treatments are medically inadvisable.

- AD involvement of ≥10% body surface area at screening and baseline.

- Stable dose of emollient twice daily (or more, as needed) for at least 14 days before
randomisation.

Exclusion Criteria:

- Active dermatologic conditions that may confound the diagnosis of AD.

- Use of tanning beds or phototherapy within 6 weeks prior to randomisation.

- Treatment with systemic immunosuppressive/immunomodulating drugs and/or systemic
corticosteroid within 4 weeks prior to randomisation.

- Treatment with TCS, TCI, or topical phosphodiesterase 4 (PDE-4) inhibitor within 2
weeks prior to randomisation.

- Receipt of any marketed biological therapy (i.e. immunoglobulin, anti immunoglobulin
E) including dupilumab or investigational biologic agents.

- Active skin infection within 1 week prior to randomisation.

- Clinically significant infection within 4 weeks prior to randomisation.

- A helminth parasitic infection within 6 months prior to the date informed consent is
obtained.

- Tuberculosis requiring treatment within the 12 months prior to screening.

- Known primary immunodeficiency disorder.